Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, ...
A new review highlights growing evidence that cyclin-dependent kinase (CDK) inhibitors—already used in over a million breast cancer patients—could benefit other cancers through novel drug combinations ...
A new review in Nature Reviews Drug Discovery highlights the potential for CDK4/6 inhibitors, currently approved for certain breast cancers, to treat a wider range of cancers. Researchers from Roswell ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...
In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results